The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
Adults with chronic spontaneous urticaria experienced greater mortality, probably due to increased risks for comorbidities, ...
Dr Adam Friedman discusses the clinical impact of CSU updates, highlighting emerging therapies, dietary insights, and patient ...
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...
8h
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD <li /> Following recent approvals in the E ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback